Moreover, Wang et al.13 showed that BCAT1 conferred sublethal tyrosine kinase inhibitor resistance in EGFR-mutated lung cancer cells through the H3K9 demethylation-mediated BCAA metabolism reprogramming. This evidence concerns the gene BCAT1 and lung cancer.